	CEP 1'8 2006	<u>ğ</u>			BN/SB/0		
Substitute	pcdorm 1449A/PTO	5/		Complete if Known			
				Application Number	10/551,263		
INFORMATION DISCLOSURE				Filing Date	March 28, 2003		
STATEMENT BY APPLICANT (use as many sheets as necessary)			PLICANT	First Named Inventor	Toshihiro NAKASHIMA		
				Group Art Unit			
			ecessary)	Examiner Name			
Sheet	1	of	3	Attorney Docket Number	NAKASHIMA6		

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/		us-			
		U\$-			
		US-			

		FOREIC	ON PATENT DO	CUMENTS		
xaminer	Cite No.1	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	ī
) <u>/</u> /A	EP 1 055 429 A1	02-15-1999	Juridical Foundation		
/00	AB	JP 09-110704	04-28-1997	Chemo Sero Therapeut		
	_		<u>_</u>			
						-
						_
						_
						_
Examin		1 101 1 1 0 1 1 1		L Data	44/00/0007	
Examın Sionatu		/Oluwatosin Ogunbiyi/		Date Considered	11/30/2007	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under MPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Considered

Signature

BN/SB/08A/B SEP 1 8 2006 Substitute for for 1449A/PTO
INFORMATION DISCLOSURE Complete if Known 10/551,263 **Application Number** March 28, 2003 **Filing Date** STATEMENT BY APPLICANT Toshihiro NAKASHIMA **First Named Inventor Group Art Unit** (use as many sheets as necessary) **Examiner Name** Sheet 2 of 3 Attorney Docket Number **NAKASHIMA6**

		NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION	
Examine Initials*	r Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
/00	O/AC	WATANABE, W. "Pharmacotherapy on juvenile rheumatoid arthritis"; Rheumatism; Vol. 36, No. 4, pp.670-675, 1996	
	AD	ICHIKAWA, Y. et al., "Methotrexate and salazosulfapyridine in the long-term treatment of rheumatoid arthritis"; Vol. 35, No. 4, pp. 663-670, 1995	
	AE	KASHIWAZAKI, S. et al., "Prospective clinical study of the combination therapy of auranofin and methotrexate for rheumatóid arthritis- a multi-center study"; Ryumachi, 1996, Vol. 36, No. 3, pp. 528-544	-
	AF	FURUTANI, T. et al., "Adverse effects of low-dose methotrexate on rheumatoid arthritis", Ryumachi, October 1996, Vol. 36, No. 5, pp.746-752	
	AG	YAMAMURA, Y. et al., "Immunodeficiency due to medicament"; Immunological Science; Vol. 9, pp.285-289, 1984	
	AH	TOTOKAWA, S. et al., "Effects of low-dose methotrexate therapy in rheumatoid arthritis: a comparison of three Different dosage regiments"; Ryumachi, October 1997, Vol. 37, No. 5, pp.681-687	
	Al	WHITE, J. et al., "The VB-Specific Superantigen Staphylococcal Enterotoxin B: Stimulation of Mature T Cells and Clonal Deletion in Neonatal Mice"; Cell, Vol. 56, pp.27-35, January 13, 1989	
	AJ	MICUSAN, V.V. et al., "Superantigens of microbial origin"; Seminars in Immunnology, Vol. 5, 1993, pp.3-11	
	AK	KIM, C. et al., "Reduction of Lupus Nephritis in MRL/lpr Mice by a Bacterial Superantigen Treatment"; J. Exp. Med, Vol. 174, December 1991, pp.1431-1437	
	AL	ROTT, O. et al., "Protection from experimental allergic encephalomyelitis by application of a bacterial antigen"; International Immunology, Vol. 4, No. 3, pp.347-353	
	AM	KUWAHATA, M. et al., "Age-related occurrence of inhibitory antibodies to streptococcal pyrogenic superantigens"; Acta Paediatricia Japonica, Vol. 38, pp.1-7, 1996	
	AN	ORIGUCHI, T. et al., "Increased levels of serum IgM antibody to staphylococcal enterotoxin B in patients with Rheumatoid arthritis"; Annals of the Rheumatic Diseases, Vol. 54, pp.713-720, 1995	

Examiner Signature	/Oluwatosin Ogunbiyi/	Date Considered	11/30/2007

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

SEP 1 8 2006		BN/SB/08A/	B'B			
Substitute for form PAAPTO	Co	mplete if Known				
PANCHART	Application Number	10/551,263	-			
INFORMATION DISCLOSURE	Filing Date	March 28, 2003	_			
STATEMENT BY APPLICANT	First Named Inventor	Toshihiro NAKASHIMA	_			
OTATEMENT BY ALL ELOAMS	Group Art Unit		_			
(use as many sheets as necessary)	Examiner Name		_			
Sheet 3 of 3	Attorney Docket Number	NAKASHIMA6	_			

	NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²			
/00	AO	NISHI, J. et al., "B Cell Epitope Mapping of the Bacterial Superantigen Staphylococcal Enterotoxin B"; The Journal of Immunology, 1997, Vol. 158, pp.247-254				
\						
			·			
	·					
	ļ					
Exami	ner	Date				
Signat	ure	Considered				

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.